-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Guide: Amitinib, a third-generation EGF-TKI inhibitor developed by Howson Pharmaceuticals, was approved for sale in China in March.
today, Hansen Pharmaceuticals announced that Henson (Shanghai) Health Technologies and Howson Pharmaceuticals have entered into strategic partnerships and license agreements with EQRx to grant EQRx exclusive licenses to develop, produce and commercialize the third generation of EGFR-TKI Amitini (and any products contained in or made up of amatinib) in the therapeutic areas of cancer, cancer-related and inflammatory diseases.
Amitinib, a third-generation EGFR (epidermal growth factor receptor) -TKI (tyrosine kinase inhibitor) developed by Haussen Pharmaceuticals, was approved in China in March this year for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have previously been treated with EGFR-TKI and are positive in the T790M mutation.
under the license agreement, Henson (Shanghai) Health Technologies and Howson Pharmaceuticals are entitled to receive down payments and registration and development milestone payments of approximately $100 million (excluding other potential commercial milestone payments and tiered royalties based on net sales).
the milestone payment must be made only if the milestone is reached and paid in the first time the milestone event has occurred.
.